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Fluconazole is a widely used antifungal agent that is extensively reabsorbed in patients with normal renal
function. However, its reabsorption can be compromised in patients with acute kidney injury, thereby leading
to altered fluconazole clearance and total systemic exposure. Here, we explore the pharmacokinetics of
fluconazole in 10 critically ill anuric patients receiving continuous venovenous hemodiafiltration (CVVHDF).
We performed Monte Carlo simulations to optimize dosing to appropriate pharmacodynamic endpoints for
this population. Pharmacokinetic profiles of initial and steady-state doses of 200 mg intravenous fluconazole
twice daily were obtained from plasma and CVVHDF effluent. Nonlinear mixed-effects modeling (NONMEM)
was used for data analysis and to perform Monte Carlo simulations. For each dosing regimen, the free drug
area under the concentration-time curve (fAUC)/MIC ratio was calculated. The percentage of patients achiev-
ing an AUC/MIC ratio greater than 25 was then compared for a range of MIC values. A two-compartment
model adequately described the disposition of fluconazole in plasma. The estimate for total fluconazole
clearance was 2.67 liters/h and was notably 2.3 times faster than previously reported in healthy volunteers. Of
this, fluconazole clearance by the CVVHDF route (CLCVVHDF) represented 62% of its total systemic clearance.
Furthermore, the predicted efficiency of CLCVVHDF decreased to 36.8% when filters were in use >48 h. Monte
Carlo simulations demonstrated that a dose of 400 mg twice daily maximizes empirical treatment against
fungal organisms with MIC up to 16 mg/liter. This is the first study we are aware of that uses Monte Carlo
simulations to inform dosing requirements in patients where tubular reabsorption of fluconazole is probably
nonexistent.
Acute kidney injury (AKI) often develops in critically ill
patients and is associated with a mortality rate as high as 60%
(3, 37). Renal replacement therapy (RRT) is therefore used
routinely as a therapeutic measure in a large proportion of
patients admitted to intensive care (18, 33). Continuous veno-
venous hemodiafiltration (CVVHDF) is a commonly used
form of RRT, in which solute removal occurs via diffusion
gradients through a countercurrent dialysate flow (11, 36). This
dialysis modality is effective at removing solutes during a 24- to
48-h period and is better tolerated by hemodynamically unsta-
ble patients than intermittent hemodiafiltration (13). However,
CVVHDF can modify the clearance of some drugs, thereby
necessitating dose adjustment to achieve therapeutic targets
(32, 33). CVVHDF is thought to be of clinical relevance only
when extracorporeal elimination exceeds 25 to 30% of total
body clearance (28).
In addition to RRT, pathophysiological changes can alter
the pharmacokinetics (PK) of drugs in the critically ill (25, 30).
Suitable drug dosage guidelines are therefore required in the
treatment of critically ill patients receiving CVVHDF or other
continuous RRT (6). This information is particularly relevant
to drug dosing in patients with AKI, for which mortality rates
are higher than those in other critical care settings (37).
Fluconazole is a triazole antimycotic agent used for the
treatment of superficial and systemic fungal infections (10). It
is recommended for patients with candidemia due to its con-
centration-dependent activity, favorable safety profile, and
proven efficacy (23). Furthermore, a free drug area under the
concentration-time curve from 0 to 24 h (fAUC0–24)/MIC ratio
greater than 25 has been suggested as the appropriate phar-
macodynamic endpoint for fluconazole efficacy (1, 7, 21). In
patients with normal renal function, fluconazole has an elimi-
nation half-life of 25 to 35 h, with 80% of the drug excreted
unchanged in the urine (10, 31). It is normally extensively
reabsorbed by the kidneys (9), and it has previously been val-
idated as a marker for renal reabsorption (35). However, in
patients with severely impaired kidney function, the ability for
tubular reabsorption is unlikely, and it could considerably alter
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the clearance of fluconazole when combined with continuous
RRT (8, 20, 26, 38, 39). As a consequence, this could signifi-
cantly influence the fAUC0–24/MIC ratio of fluconazole,
thereby compromising its desired therapeutic response.
In this study, we developed a population PK model to de-
scribe the disposition of fluconazole in anuric patients receiv-
ing CVVHDF. We then performed Monte Carlo dosing sim-
ulations to demonstrate that dose adjustment is required to
maximize the opportunity for therapeutic outcomes in these
patients.
MATERIALS AND METHODS
Patients. This study was conducted at the Royal Brisbane and Women’s
Hospital (Queensland, Australia) over a 28-month period. Ethical approval was
obtained from the Royal Brisbane Hospital Research Ethics Committee and the
Medical Research Ethics Committee of the University of Queensland. Informed
consent was obtained from the patient or next of kin. Patients were enrolled if
they were 17 years of age, critically ill, required CVVHDF for renal failure of
any cause, and were prescribed fluconazole for a suspected infection. Patients
were excluded if informed consent was declined or could not be obtained.
Dialysis prescription. For all patients, CVVHDF was performed with predi-
lution filtration solution (2 liters h1) and dialysate (1 liters h1), giving a 3 liters
h1 dialysis effluent. Fluid input and effluent rates were set at 999 ml h1 and
were controlled using IMED PC4 volumetric pumps (Alaris Medical Systems
Inc., San Diego, CA). Blood was pumped (200 ml min1) using a Gambro
BMM-10 pump (Gambro AB, Stockholm, Sweden) through an extracorporeal
circuit containing a Hospal AN69HF hemofilter (Hospal AG, Lyon, France).
With the exception of patient 4, all patients had filters in use 48 h at the start
of CVVHDF treatment. For all patients (except 1 and 5), dialysis commenced
prior to fluconazole dosing.
Dosing and sample collection. A standard 200 mg dose of fluconazole was
administered twice daily as a 60-min intravenous (i.v.) infusion. Blood was
obtained from an indwelling arterial cannula during the infusion (30 min), at the
end of the infusion (1 h), and after 2, 3, 4, 6, 8, and 12 h. The blood samples were
collected in heparinized tubes and chilled on ice and then centrifuged (2,000 
g for 5 min at 4°C) within 1 h to obtain plasma. CVVHDF effluent was sampled
every hour over 12 h from all patients. All samples were subsequently stored at
80°C until analysis.
For patients 3, 4, and 8, blood and CVVHDF effluent sampling was performed
on the first day of fluconazole treatment to obtain an initial profile. In all other
patients, blood and CVVHDF effluent were collected on day 3 or day 5 to
provide a steady-state profile. In the latter group of patients, a 12-h sample was
obtained immediately prior to administration of the next dose. No data from
both initial and steady-state profiles were available for any of the patients en-
rolled in the study.
Determination of plasma and CVVHDF concentrations. The concentrations of
fluconazole in plasma were measured by high-performance liquid chromatogra-
phy, as reported previously (19). Analysis of drug concentrations in the
CVVHDF effluent was performed by adapting the same assay for urine. Stan-
dard curves were prepared at 0.2 to 20 mg/liter (plasma) and 2.0 to 200 mg/liter
(effluent). The limit of quantitation was 0.2 mg/liter for plasma and 2.0 mg/liter
for CVVHDF samples. In both matrices, intraday and interday precision were
below 12%.
Population PK modeling. The concentration-time data for fluconazole in
plasma were fitted to one-, two-, or three-compartment models by nonlinear
mixed-effects modeling (NONMEM version 6.1; Globomax LLC, Hanover, MD)
(5). A Digital Fortran compiler was used, and the runs were executed using
Wings for NONMEM (http://wfn.sourceforge.net). Data were analyzed using the
first-order conditional estimation method with interaction and ADVAN6 to
solve the differential equations. Between-subject variability (BSV) was calculated
using an exponential variability model and was assumed to follow a lognormal
distribution. Residual unexplained variability (RUV) was modeled using a com-
bined exponential and additive random error. Visual inspection of diagnostic
scatter plots and the NONMEM objective function value (OBJ) were used to
evaluate goodness of fit. Statistical comparison of nested models was undertaken
using the NONMEM program on the basis of a 2 test of the difference in OBJ.
A decrease in the OBJ of 3.84 units (P  0.05) was considered statistically
significant.
Covariate screening. A forwards and backwards stepwise approach was used to
include the following covariates: age, total body weight, sex, and APACHE II
score into the model. Covariates were included if they were biologically plausible
and if the decrease in OBJ was at least 3.84 units.
CVVHDF model. A CVVHDF model was developed by partitioning total
fluconazole clearance from the central compartment into CVVHDF
(CLCVVHDF) and non-CVVHDF (CLNCVVHDF) routes. CLCVVHDF was then
modeled by simultaneously fitting cumulative amounts of fluconazole in the
CVVHDF effluent with its concentration-time data in plasma.
Model evaluation. The final CVVHDF model was evaluated by performing a
visual predictive check (VPC) and by nonparametric bootstrapping with resam-
pling and replacement (24). For the VPC, 1,000 data sets were simulated from
the final parameter estimates using the original data as a template. The median,
10th, and 90th percentiles of simulated concentrations were then computed and
plotted against observed values. A nonparametric bootstrap method was used to
assess the uncertainty of all parameter estimates in the final model. The 2.5th,
50th, and 97.5th percentiles for all parameters were calculated from the empir-
ical posterior distribution of 1,000 bootstrap replicates. Eta shrinkage was eval-
uated to identify model suitability for performing dose simulations and for the
addition of covariates into the model.
Dosing simulations. Monte Carlo simulations for fluconazole dosing with
CVVHDF treatment were undertaken using NONMEM. The simulations in-
cluded a standard dose of 200 mg twice daily, a loading dose (LD) of 400 mg, 800
mg, and 1,600 mg, followed by a standard dose of 200 mg twice a day and 400 mg
twice daily. For each dosing schedule, the Monte Carlo simulations generated
concentration-time profiles, fAUC0–24 values, and fAUC/MIC ratios for 1,000
subjects, using the parameters from the final model. The MICs utilized ranged
from 0.0625 mg/liter to 32 mg/liter, as this is likely to represent the maximal
spectrum of candidemia treated with fluconazole in critical care (Clinical and
Laboratory Standards Institute [CLSI] breakpoints for antifungal agents). For
each dosage regimen, the probability of target attainment (PTA) was calculated
as the percentage of patients achieving a fAUC/MIC ratio of 25 for a given
MIC. An additional analysis was also performed using a fAUC/MIC ratio of
100 based on clinical experience, as defined by European Committee on An-
timicrobial Susceptibility Testing (EUCAST) methodology (http://www.srga.org
/eucastwt/MICTAB/index.html). For both analyses, the PTA was plotted against
the range of MICs.
RESULTS
Population PK analysis. A total of 10 anuric patients were
enrolled in this study, requiring i.v. fluconazole for a suspected
fungal infection while receiving CVVHDF. Eight of the 10
patients had normal liver function. For the two patients with
abnormal liver function, one patient had four times the upper
limit of alanine aminotransferase (ALT) (145 u/liters), and the
other patient had four times the upper limit of aspartate ami-
notransferase (AST) (168 u/liters). Albumin concentrations
were low in all patients, ranging from 11 to 30 g/liter. Demo-
graphic information for the 10 patients is provided in Table 1.
The time course of fluconazole in plasma was best described
by a two-compartment model with combined residual error,
BSV on clearance, central volume of distribution, and infusion
duration. Input into the central compartment was fitted by
zero-order kinetics.
Covariate screening. After screening all biologically plausi-
ble covariates on clearance and volume of distribution, no
statistically significant improvements in the base model were
found. None of the covariates tested were therefore incorpo-
rated into the model for fluconazole in plasma.
CVVHDF model. Cumulative amounts of fluconazole in the
CVVHDF effluent were combined with the plasma concentra-
tion-time data to allow for estimation of CLCVVHDF (Fig. 1).
The residual variability for the amount of fluconazole in the
CVVHDF effluent was best described by an additive error
model. When the effect of filter age was included as a covari-
ate, the BSV on CLCVVHDF was reduced from 34.4% to 19.8%,
with a significant drop in objective function (OBJ  11.46).
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This model predicted that the efficiency of CLCVVHDF de-
creased to 36.8%, when filters were in use 48 h. Table 2
summarizes the parameter estimates for the final model, to-
gether with their median, 2.5th, and 97.5th percentiles from all
bootstrap replicates. The population estimate for CLCVVHDF
(1.66 liters/h) represented 62% of total fluconazole clearance
from the central compartment, where CLNCVVHDF was 1.01
liters/h. For the latter clearance (CLNCVVHDF), the estimate
for BSV (77.1%) was relatively high.
Model evaluation by VPC and bootstrapping. The VPC for
fluconazole in plasma and in CVVHDF effluent is presented in
Fig. 2. Approximately 15 to 20% of the data lie outside the
10th and 90th percentiles, with the majority of observed con-
centrations evenly distributed around the median (Fig. 2, top).
In addition, prediction percentiles closely match correspond-
ing observation percentiles (Fig. 2, bottom). Furthermore, me-
dian values for all parameters from the bootstrap analysis were
similar to those in the final model (Table 2) and were within
their respective 95th percentile range. Evaluation of eta
shrinkage on clearance (0.03), volume of distribution (0.1), and
infusion duration (0.08) suggested that none of the parameters
were poorly estimated. These results confirm the suitability of
the model for describing fluconazole disposition in this popu-
lation, making it suitable for simulating new potential dosing
regimens in this group.
Dosing guidelines. Multiple dosing regimens were assessed
on the basis of the final model and by using MIC values ranging
from 0.0625 mg/liter to 32 mg/liter. The abilities of the differ-
ent dosing schedules to achieve a predefined pharmacody-
namic endpoint (fAUC/MIC  25) were then calculated and
compared. Figure 3A shows that a 200 mg LD is ineffective for
a MIC of 1 mg/liter for the first 12 h after initialization of
fluconazole treatment. A 400 mg and 1,600 mg LD is required
to achieve attainment for MIC of 1 mg/liter and 4 mg/liter,
respectively. Similar PTA is obtained for a dose of 400 mg
twice daily and a 400 mg LD with subsequent dosing of 200 mg
twice daily (Fig. 3B). At steady state (60 h), the current dose
(200 mg twice daily) performs better in subjects with normal
renal function than in anuric patients receiving CVVHDF (Fig.
3C). For the CVVHDF patients, a dose of 400 mg twice daily
provides similar or slightly better PTA for the treatment of
fungal infection, with MIC values up to 16 mg/liter. For all
dosing regimens, a 4-fold dose increase is required to achieve
the pharmacodynamic endpoint of a fAUC/MIC ratio of 100
(Fig. 3D to F) compared to a fAUC/MIC ratio of 25.
DISCUSSION
The present study develops a population PK model that
describes the disposition of fluconazole in critically ill anuric
patients receiving CVVHDF. This model is then used to iden-
tify dosing schedules that achieve the pharmacodynamic end-
points that should be associated with optimal fluconazole ac-
tivity. We show that a significant dose increase (doubling) is
required for the treatment of fungal infection in anuric pa-
tients for whom CVVHDF with the stated settings is also
prescribed. This is the first study we are aware of that uses
Monte Carlo simulations in this patient population to inform
dosing requirements of fluconazole.
In the final covariate model, the estimate for total flucona-
zole clearance by CVVHDF and non-CVVHDF routes (2.67
liters/h) is considerably faster than that previously reported
(1.18 liters/h) for healthy patients (31). Differences in clear-
ance are expected with renal insufficiency, particularly for
drugs that are predominantly eliminated via the kidneys (17,
35). A possible explanation for this relatively faster clearance
in people receiving CVVHDF is that tubular reabsorption is
probably nonexistent in anuric patients, and there is no ability
TABLE 1. Demographic and clinical information of enrolled patients
Patient Age (yr) wt (kg)a Sex APACHE IIscoreb Diagnosis on admission Site of infection Causative organism
1 66 55 F 22 Medical Urinary tract Candida albicans
2 68 50 F 43 Medical Lung Nonfungal
3 70 80 M 38 Medical Lung Candida albicans
4 69 80 M 19 Emergency; surgery Intraabdominal Candida albicans
5 62 80 M 20 Emergency; surgery Intraabdominal Candida albicans
6 51 104 F 17 Emergency; surgery Intraabdominal Candida albicans
7 72 80 M 44 Emergency; surgery Blood Candida albicans
8 67 100 M 30 Medical Indwelling vascular catheter Candida parapsilosis
9 76 75 F 28 Medical Urinary tract Candida albicans
10 59 72 F 31 Medical Urinary tract Candida albicans
a Estimated weight at time of treatment.
b APACHE II score, acute physiology and chronic health evaluation II score on admission.
FIG. 1. Structural model for the estimation of fluconazole clear-
ance by CVVHDF (CLCVVHD) and non-CVVHDF (CLnon-CVVHD)
pathways. The time course of fluconazole in plasma was best described
by a two-compartment model with zero order input.
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for reabsorption via the CVVHDF process. This assertion is
not unreasonable, given that fluconazole is extensively reab-
sorbed in subjects with normal renal function (9) and is there-
fore used as a marker of reabsorption in renal cocktails (35).
Extracorporeal elimination by CVVHDF accounted for ap-
proximately 62% of total fluconazole clearance, with a BSV of
19.8% when the effect of filter age was included in the model
(Table 2). The corresponding BSV for non-CVVHDF clear-
ance was relatively high (77%), which we suggest is expected
due to the disease status of these critically ill patients. Of note
was our finding that filters in use 48 h considerably reduced
the efficiency of dialysis to 37% of total fluconazole clearance,
TABLE 2. Population parameter estimates for the final fluconazole CVVHDF model and the 1,000 bootstrap runs
Parameter Description Unit CVVHDF modelestimate
1,000 bootstrap replicates
Median 95th percentileb
CLCVVHDF Clearance of fluconazole by CVVHDF Liters/h 1.66 1.65 1.45–1.92
CLNCVVHDF Non-CVVHDF clearance of fluconazole Liters/h 1.01 0.95 0.42–1.56
Vc Central vol of distribution Liters 31.7 29.8 9.3–47.0
Q Intercompartmental clearance Liters/h 27.6 30.8 5.4–70.1
Vp Peripheral vol of distribution Liters 21.9 23.9 15.0–38.5
D1 Duration of intravenous infusion h 0.689 0.701 0.570–0.885
ffCLCVVHDF Effect of filter in use 48 h on CLCVVHDF 0.368 0.368 0.326–0.426
BSV CLCVVHDF Between-subject variability in CLCVVHDF CV
a 19.8 18.6 9.90–26.3
BSV CLNCVVHDF Between-subject variability in CLNCVVHDF CV 77.1 78.0 20.5–156
BSV Vc Between-subject variability in VC CV 22.9 23.8 8.40–93.5
BSV D1 Between-subject variability in D1 CV 23.0 20.3 0–55.1
RUVSDP Additive residual error in plasma mg/liters 0.239 0.233 0–0.410
RUVCVP Exponential residual error in plasma CV 3.67 3.73 0–6.67
RUVSDC Additive residual error in CVVHDF mg/liters 2.84 2.77 1.31–3.71
a CV, coefficient of variation (%).
b 2.5th and 97.5th percentile range.
FIG. 2. Visual predictive check for fluconazole in plasma (A and C) and in the CVVHDF effluent (B and D). Top panels show the observations
for initial (E) and steady-state (F) profiles, with model-predicted median (solid lines) and 10th and 90th percentiles (dashed lines). Bottom panels
illustrate that predicted percentiles (black lines) closely match corresponding observed percentiles (gray lines).
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which could explain some of the random BSV associated with
CVVHDF clearance. However, while this finding appears of
clinical relevance, caution must be applied, since only 1 patient
received CVVHDF treatment with a 48-h filter. Further data
are required to confirm the long-term effects of filter age on
fluconazole clearance. Alternatively, a cautious approach
would be to recommend filter changes more frequently than
every 48 h to enable more predictable clearance of fluconazole.
The steady-state volume of distribution (Vc plus Vp) for
fluconazole in this cohort of patients (53.6 liters) was consis-
tent with that previously reported (55.7 liters) in healthy vol-
unteers (31). However, the disposition of fluconazole was best
described by a one-compartment model in the latter study,
unlike the two-compartment model presented here. One pos-
sible reason for the existence of a peripheral compartment is
drug redistribution, which could arise due to leaky capillaries
and other pathophysiological changes in critically ill patients
(25, 30).
Monte Carlo dosing simulations were performed to calcu-
late the probability of achieving pharmacodynamically relevant
fAUC/MIC ratios following fluconazole treatment. These were
necessary as the enhanced fluconazole clearance in this
CVVHDF group will result in considerably smaller AUC val-
ues than those in healthy subjects. Two different fAUC/MIC
breakpoints were applied to reflect potentially more severe
infections, as well as the uncertainty in PK/PD target values
required for successful therapy. This also accounts for the
different types of data that were utilized to determine PK/PD
target values by CLSI and EUCAST. The simulations include
the first 12 h following dosing, since early attainment of ther-
apeutic target concentrations is essential to improve efficacy
during antimicrobial therapy (15, 16, 27). At 12 h postinitial-
ization of treatment, a standard loading dose of 200 mg is
effective only for MICs up to 1 mg/liter when using the target
of a fAUC/MIC ratio of 25 (Fig. 3A). For early attainment
beyond this 1 mg/liter MIC value, higher loading doses are
required and can be directly obtained from Fig. 3A. At steady
state (60 h post initial dose), a dose of 400 mg twice a day
maximizes treatment against Candida with MIC values up to
16 mg/liter (Fig. 3C). For attainment of fAUC/MIC values of
100, a 4-fold dose increase is required compared to the
fAUC/MIC target of 25 (Fig. 3D to F). Several studies have
previously recommended a daily dose of 800 mg with
CVVHDF (4, 8, 12, 14, 20, 22, 26, 36, 39). However, due to
study design and analysis methods, these recommendations do
not accurately identify between-subject variability, the effect of
covariates such as filter age, or the likely probability of attain-
ment at steady state. The study presented here is the first and
largest study to date that considers fluconazole dosing in pa-
tients that are likely to lack renal tubular reabsorption. Fur-
thermore, the analysis method utilized (NONMEM), appro-
priately handles the issues of between-subject variability and
covariate inclusion. Clearly, the current dose of 200 mg twice
daily performs worse in anuric patients compared to that in
healthy volunteers.
Several potential limitations of using Monte Carlo simula-
tions must be considered. First, a small sample size (10 sub-
jects) was used in the current study, and this may not represent
the true PK variability in a population of critical care patients
(29, 34). However, the recruitment of large numbers of criti-
FIG. 3. Simulation data for the probability of target attainment (PTA) following fluconazole dosing in patients receiving CVVHDF. The
dosing schedules included loading doses (LD) ranging from 200 mg to 1,600 mg (A and D), a standard dose of 200 mg twice daily following
the range of LD (B and E), and the effect of CVVHDF treatment relative to that of patients with normal renal function (C and F). A PTA
of 1.0 was defined when fAUC/MIC ratios exceeded 25 (A to C) and 100 (D to F). Parameters for patients with normal renal function were
obtained from reference 31.
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cally ill patients is challenging, and simulations based on small
cohorts are instructive for assessing altered dosing strategies,
especially when it is clear that a large change in dosage from
the usual is required to attain suitable concentrations. A sec-
ond limitation is the use of published MIC data, given that the
susceptibilities of Candida species can vary over time, between
countries and between hospitals (29, 30). For this reason, a
range of MIC values (0.0625 to 32 mg/liter) was used in the
present study, such that suitable dosing schedules for an or-
ganism resistance patterns can be determined from data shown
in Fig. 3. Falsely high PTA could arise if modeling free drug
concentration in healthy subjects (plasma protein binding,
10%) as opposed to that in critical care patients. However,
this is unlikely to confound the results presented here, since
the plasma protein binding of fluconazole is only slightly higher
(22%) in critically ill patients (2). Finally, the dosing simula-
tions presented here are representative of patients receiving
adequate or average filtration. On this basis, target concentra-
tion intervention (TCI) could be considered to further opti-
mize fluconazole dosing if subtherapeutic exposure is sus-
pected due to organisms with high MICs or if dialysis filter
clotting is an issue.
Conclusions. Fluconazole is an important antimycotic agent
that is used for the treatment of fungal infections across a wide
range of patient populations. However, when used in anuric
patients receiving CVVHDF, the total clearance of fluconazole
is significantly increased. In this study, we show that doubling
the current dose of 200 mg twice daily (to 400 mg twice daily)
better achieves the pharmacodynamic endpoint associated
with optimal antifungal activity. A dose increase is therefore
highly recommended in similar patient cohorts prescribed both
CVVHDF and fluconazole treatment.
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